Free-text search
Articles per year:
Content Types
-
US lawsuits target GLP‑1 manufacturers over alleged link to vision damage
Dozens of patients in the United States have sued Novo, the manufacturer of Ozempic and Wegovy, alleging that the drugs caused vision loss.
-
“Considerable anxiety” at Mölnlycke as 150 jobs face cuts
Around 150 jobs could be affected by Mölnlycke’s planned cuts. Local unions tell Life Science Focus that employees are facing growing uncertainty as they wait to learn which parts of the organisation will be affected.
-
12 new medicines recommended for EU approval
A treatment for haemophilia and a rabies vaccine are among the new medicines recommended for approval by EMA’s Committee for Medicinal Products for Human Use (CHMP).
-
Staffing questions remain as Mölnlycke prepares to split
Mölnlycke’s planned split is intended to create two stronger companies. But several questions about the separation remain open, including how the organisation will be affected.
-
FDA clears 3.95 million dollar gene therapy
For the first time, there is now an approved gene therapy for Sanfilippo syndrome type A. The disease is extremely rare, and the treatment is among the most expensive in the world — with a list price of nearly four million dollars.
-
Pepaxti gets regulatory boost – Oncopeptides shares jump
Oncopeptides is moving closer to expanding the use of its multiple myeloma drug Pepaxti in Europe. The Swedish biotech company’s shares rose by around 20 per cent in early trading on Friday following the regulatory announcement.
-
Sciety names new CEO to succeed co-founder
Life science investment firm Sciety has appointed a new CEO. Anna Sundin takes over from co-founder Andreas Lindblom, who is stepping down as chief executive but will remain in an operational role at the company.
-
Novartis expands brain‑delivery push with Sironax deal
Novartis continues to invest in new methods for the efficient delivery of medicines to the brain.
-
Novo Nordisk enters billion-dollar collaboration with Orbis Medicines
Danish pharmaceutical company Novo Nordisk has entered into a strategic collaboration and licensing agreement with fellow Danish company Orbis Medicines to develop next-generation oral medicines for cardiometabolic diseases. This is stated in a press release.
-
A new name for a broader outlook
Life science is, by its very nature, an international industry. Companies, research and people move across borders – and anyone covering the sector needs to do the same.
-
Stem cell setback in infant heart condition
U.S.-based Longeveron plans to implement cost‑saving measures and “explore strategic options” after a Phase II trial failed to meet its primary endpoint in a rare congenital heart condition in infants.
-
Bavarian Nordic names Tarja Stenvall new CEO
Danish vaccine maker Bavarian Nordic has appointed Tarja Stenvall as its new President and CEO, succeeding Paul Chaplin.
-
Rarity Bioscience targets hidden disease signal with new test
Rarity Bioscience has a lot going on. The Uppsala-based company is launching an ultra-sensitive blood test for systemic mastocytosis while preparing to move into premises more than twice the size at Uppsala Business Park.
-
Mölnlycke to split into two companies
The Swedish medtech company Mölnlycke plans to separate its Operating Room Solutions (ORS) and Gloves businesses into a new stand-alone company, Mölnlycke Surgical. The change is expected to be completed during 2027.
-
Novo partners with AI giant
Novo and AI specialists Anthropic will partner to advance drug discovery.
-
17 companies receive millions from BII: “We are facing a historic opportunity”
The Danish BioInnovation Institute will provide convertible loans for 17 startup companies
-
Sanofi to transfer 20 medicines to Cheplapharm
Sanofi will transfer 20 of its established medicines and three manufacturing sites to Germany‑based Cheplapharm. The move is said to be partly aimed at freeing up resources for the development of new medicines.
-
Axoltis moves ALS drug forward after encouraging clinical findings
A new ALS candidate from French company Axoltis Pharma missed its primary endpoint in a Phase II study but showed several positive clinical effects.
-
David Lang on the future of robotic surgery: More people should gain access
David Lang, Head of the Nordic Region at robotic surgery company Intuitive, delivers the opening address at Medtechdagen 2026 next week. On stage, he will discuss the field’s development and how the technology can benefit more patients.
-
Novo walks away from Ascendis GLP‑1 partnership
Novo is terminating a licensing partnership with Ascendis Pharma, thereby leaving behind a development program in weight management after two years.
-
Lilly is sanctioned for remarks to Swedish media
Eli Lilly is being sanctioned for statements made in an interview with a Swedish newspaper, in which a yet‑to‑be‑approved obesity drug is claimed to “stand in a class of its own”.
-
Ambu acquires US endoscopy company
Danish medtech company Ambu has acquired US-based TIMS Medical for USD 45m, with additional milestone payments of up to USD 20m.
-
FDA approves first SMA therapy targeting muscle loss
A new type of medication for the rare genetic disease spinal muscular atrophy (SMA) has been approved in the United States.
-
Tataa is acquired by a Dutch firm
The Swedish laboratory company TATAA Biocenter is being acquired by the Dutch CRO Single Cell Discoveries.
BREAKING